Shares of Biomarin Pharmaceutical (NASDAQ:BMRN) decreased in after-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 79.55% over the past year to $0.09, which beat the estimate of ($0.10).

Revenue of $486,030,000 decreased by 3.19% year over year, which beat the estimate of $446,450,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

The upcoming fiscal year's revenue expected to be between $1,750,000,000 and $1,850,000,000.

Details Of The Call

Date: Apr 29, 2021

Time: 04:30 PM

ET Webcast URL: https://onlinexperiences.com/scripts/Server.nxp?LASCmd=AI:4;F:QS!10100&ShowUUID=F1263B20-BE46-4ECA-876D-F6FFD8F51EF3&Referrer=https%3A%2F%2Finvestors.biomarin.com%2F

Recent Stock Performance

52-week high: $131.94

52-week low: $71.35

Price action over last quarter: Up 0.74%

Company Profile